Interview: Summit Hits The Heights With Billionaire Backing
Executive Summary
Ex-Pharmacyclics CEO Bob Duggan is to invest $25m into Summit Therapeutics, taking a near 49% stake in the UK firm and helping it fund Phase III trials for the Oxford-based firm's lead antibiotic candidate ridinilazole.